Every year, hundreds of thousands of people contract chikungunya virus, a mosquito-borne illness known for its debilitating fever and intense joint pain. While many recover within weeks, roughly half of those infected face a far grimmer reality: chronic, relapsing arthralgia and arthritis that can persist for years, with no effective treatment currently available.

This enduring mystery — why some patients develop long-term joint pain while others do not — has long baffled scientists. Now, a team led by immunologist Thomas "Tem" Morrison, Ph.D., at the University of Colorado Anschutz School of Medicine, has uncovered a critical piece of the puzzle: the virus persists in specialized white blood cells called macrophages within joint-associated tissues.

The findings, published in Nature Microbiology, suggest that these macrophages act as a "sanctuary" for the chikungunya virus, allowing it to evade the immune system and drive chronic symptoms. This discovery reframes the understanding of chronic chikungunya and opens new avenues for developing targeted therapies, particularly for the resource-limited regions hardest hit by the virus.

The Lingering Threat of Chikungunya

Chikungunya virus, transmitted by Aedes mosquitoes, has seen a global resurgence. In the first nine months of 2025 alone, the World Health Organization reported over 445,000 cases and 155 deaths across 40 countries. Initial symptoms, typically appearing four to eight days after exposure, include high fever, headache, nausea, fatigue, rash, and severe joint pain and swelling. For many, these acute symptoms subside within a few weeks.

However, for an estimated 50 percent of patients, the intense joint pain and swelling morph into a chronic condition. This persistent arthralgia and arthritis can severely impact quality of life, making physical labor — often a necessity for financial well-being in affected regions — incredibly difficult.

Previous hypotheses for chronic chikungunya included the virus triggering an autoimmune response, similar to rheumatoid arthritis. Yet, supporting research for this theory has remained inconclusive. Dr. Morrison's lab, however, has been exploring a different path: the idea of a long-term persistent infection where the immune response fails to fully eliminate the virus from certain tissues.

Macrophages: A Viral Sanctuary

"This is known to occur in virus infections where the immune response can clear the infection from some parts of the body but struggles or fails to clear the infection from other parts of the body," Morrison explains. "So, this is a virus that gets into people, and it spreads systemically. It gets into a lot of tissues. The idea here is that the immune response is unable to clear it from certain tissues, and in this case, those are the joint-associated tissues."

For years, the Morrison Lab had detected long-term infection in joint-associated tissues. Their latest study, co-authored by Kristen Zarrella, Ph.D., Ryan Sheridan, Ph.D., and Brian Ware, delved deeper. The team employed advanced techniques, including single-cell RNA sequencing and spatial transcriptomics, to map gene activity and profile individual cells within infected animal models. These methods allowed them to pinpoint precisely which cell types were harboring the virus within the joint tissues.

Their findings confirmed that chikungunya virus persists specifically within macrophages, a type of white blood cell crucial for immune defense. These cells, typically responsible for engulfing and digesting pathogens, appear to be inadvertently providing a safe haven for the virus, allowing it to continue replicating at low levels and contribute to ongoing inflammation and pain.

What Experts Say

Dr. Morrison emphasizes the real-world impact of their work. "We've been interested in trying to better understand how this infection leads to chronic symptoms," he states. "Mosquito-transmitted viruses are significant problems in resource-limited regions of the world where many people rely on physical work for their financial well-being. Having chronic musculoskeletal pain is a big problem for people who contract the virus."

The researchers also addressed whether the detected persistent infection was actively contributing to the disease or merely an inert presence. By utilizing small molecule antivirals that inhibit viral replication, they were able to demonstrate that the virus harbored within macrophages was indeed driving the chronic symptoms. This crucial step confirms the direct link between viral persistence and long-term disease.

Key Takeaways

  • Approximately half of all chikungunya virus infections lead to chronic joint pain and arthritis.
  • New research identifies joint-associated macrophages as a "sanctuary" where the virus persists, evading the immune system.
  • Advanced techniques like single-cell RNA sequencing confirmed the virus's presence in these specific cell populations.
  • The persistent virus in macrophages directly contributes to the chronic symptoms, opening doors for targeted antiviral treatments.

This breakthrough offers a clear target for therapeutic intervention. The next critical step will be to translate these findings into human studies and develop antiviral strategies specifically designed to eliminate the virus from these macrophage reservoirs. Success could mean not just managing symptoms, but potentially curing chronic chikungunya, offering relief to millions worldwide.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.